CStone Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
C1 Building 218 Xinghu Street North Bloc...Phone Number
+86 51287186550Website
www.cstonepharma.comRevenue
$63.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About CStone Pharmaceuticals
CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received eight drug approvals for four drugs. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.Explore more
CStone Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CStone Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if CStone Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if CStone Pharmaceuticals had a recent Job posting/layoffs
CStone Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if CStone Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at CStone Pharmaceuticals
Earning: See what the market has to say on CStone Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once CStone Pharmaceuticals has new funding data
Product Launch: Get notified when CStone Pharmaceuticals launches new products
Recommended Actions
Reach out to Masked Content who joined CStone Pharmaceuticals as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
CStone Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CStone Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CStone Pharmaceuticals.
CStone Pharmaceuticals financials insights
Gather financial insights about CStone Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$262M
CStone Pharmaceuticals Tech Stack
A closer look at the technologies used by CStone Pharmaceuticals
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Project
Product Development, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Project
Research & Development, Compliance, Medical Research, Pharmaceuticals, Regulations
Left Company
Executive Move
Board of Directors
CStone Pharmaceuticals News & Media
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Key Highlights: Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with 23% incidence of Grade ≥3 Treatment-Related Adverse Events (TRAEs). No excessive toxicities that typically occurred in combination therapies containing CTLA-4 and PD-(L)1 were observed, and the incidence of GradeCStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody
SHANGHAI, Dec. 22, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission of clinical trial application in Australia for CS2009...CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates
Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million Healthy financial position with cash reserves of RMB 1,026.7 million as of December 31, 2023 and net loss narrowed by 57% from the past year CStone established strategic collaborations with multiple companies to maximize commercialization efficiency and product value. Manufacturing localization of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib) proceed smoothly in China, expecting significant reduction ofCStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights. The deal enables Servier to potentially bring additional indications and accessibility of TIBSOVO® to patients in Greater China (including mainland, Hong Kong, Macau, and Taiwan) and Singapore. CStone to receive up to 50 million USD to monetize some future cash flow while recouping its historical investment on the asset. SUZHOU, China and PARIS, Dec. 2
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding CStone Pharmaceuticals
Sign Up For FreeTo access detailed company insights
CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience... Read More
